In Reply First, we thank Dr. Pirodda for the interest in our article and the intriguing comments and suggestions. As Dr. Pirodda indicated, there is a striking contrast between our study (1) and the recently published study by Kim et al. (2). Dr. Pirodda raised concerns about the heterogeneity of age in our study as a result of including both patients with compromised vascular conditions and patients free from vascular risks. As described in our study, however, the age range from 9 to 90 years applied to all of the patients with idiopathic sudden sensorineural hearing loss (ISSNHL) initially found in a chart review and not to the patients with ISSNHL with benign paroxysmal positional vertigo (BPPV) who were ultimately included in this study. Indeed, the age of the patients with ISSNHL and BPPV (n = 32) ranged from 14 to 68 years (Fig. 1). Because the control group (ISSNHL without BPPV) was near-perfect age-matched with the BPPV group, the difference in the hearing outcome between the 2 groups cannot be ascribed to the age distribution. Moreover, not only age but also almost all of the hitherto-alleged prognostic factors were controlled by excluding patients with diabetes or treatment delay. Therefore, we believe that BPPV itself is an indicator of severe disease and a poor prognosis (1).FIG. 1: Age distribution of the patient and control groups in our study.It is mandatory to select treatment options that consider an individual patient’s risk factors. Needless to say the addition of anti-platelet agents in patients with more vascular risks or the precaution of using a volume expander in patients with heart problems or renal failure, treatment for ISSNHL should follow standard protocols based on evidence-based medicine. Previously, several treatment options aimed to increase inner ear perfusion have been tried in an attempt to restore hearing loss. Because only high-dose steroid therapy is accepted as beneficial (3), we use systemic steroid as a mainstay for treating ISSNHL. In line with a previous study (4), ISSNHL patients with simultaneous onset of BPPV had worse initial hearing than those without BPPV, and the improvement was less in the BPPV group than in the control group in our study. The involvement of multiple semicircular canals (19%) and a substantial proportion of recurrences of BPPV (41%) also were remarkable findings of comorbid BPPV in ISSNHL patients. Delayed BPPV can follow acute-onset paralytic vestibulopathy in neurolabyrinthitis or vestibular neuritis, in which the most plausible pathogenic mechanism is secondary degeneration of the utricle after viral or vascular insults to the inner ear or VIIIth cranial nerve territory. By contrast, in simultaneous-onset BPPV and ISSNHL, the initial insult is more likely to be focused on the inner ear, or if the lesion is on the VIIIth nerve, the insult may be severe enough to produce mechanical dislodgement of the otolith particles from the macula utriculi without delay. We speculated that these different pathogenetic mechanisms may be responsible for the poor prognosis and different steroid responsiveness in ISSNHL patients with comorbid BPPV. We hope that this letter is helpful for clarifying the issues raised and prompts further studies to elucidate the mechanisms involved in and prognosis of simultaneous BPPV in ISSNHL. Jae-Jin Song, M.D., Ph.D. Department of Otorhinolaryngology–Head and Neck Surgery, Seoul National University Bundang Hospital, Seongnam, Korea Ji Soo Kim, M.D., Ph.D. Department of Neurology Surgery, Seoul National University Bundang Hospital, Seongnam, Korea Ja-Won Koo, M.D., Ph.D. Department of Otorhinolaryngology–Head and Neck Surgery, Seoul National University Bundang Hospital Seongnam, Korea and Sensory Organ Research Institute Seoul National University Medical Research Center Seoul, Korea [email protected]
Read full abstract